Improves identification of anxiety for clinical care and trial assessments in PD but provides limited direct mechanistic or therapeutic discovery insights.

Resolving artifact versus biological signal improves confidence in beta-burst–based biomarkers and electrophysiology-driven trial endpoints, but the paper is low on direct therapeutic mechanisms or translational interventions.

Refines genotype–phenotype characterization that can improve early diagnosis and patient stratification for studies, but presents limited immediate therapeutic or mechanistic insights (abstract missing), so its direct value for drug discovery is low.

Provides a scalable, noninvasive method to quantify motor symptoms and generate clinical biomarkers useful for patient stratification and trial endpoints, but offers little insight into disease mechanisms or therapeutic targets.

Could improve early detection and patient stratification for trials, but offers little direct actionable mechanistic or therapeutic insight for Parkinson's disease drug discovery.

Network signatures can point to biomarkers or convergent pathways for therapeutic targeting and repurposing, but without accessible data or methods this manuscript currently has low actionable value for Parkinson's drug discovery.

The work pertains to diagnostic/biomarker development—which can aid patient stratification and trials—but as a correction with no new data it offers minimal direct value for therapeutic discovery or mechanistic insights.

Offers a validated clinical outcome measure useful for assessing symptom burden and tracking intervention effects in trials, but provides minimal mechanistic or therapeutic-discovery insight.

Although the correction itself offers little actionable therapeutic information, refined conceptual frameworks can still help align biomarker-based patient stratification and research priorities that indirectly support future drug discovery efforts.

Improves clinical staging and may aid patient selection for advanced therapies or trials, but provides little mechanistic or translational insight relevant to therapeutic discovery.

Helpful for clinical management, fall-prevention strategies, and designing trial endpoints or stratification, but offers little direct insight or actionable leads for Parkinson's therapeutic discovery.

Low translational value for Parkinson's drug discovery—may modestly inform symptom recognition and symptomatic care but offers no actionable pathways, biomarkers, or repurposing leads.

Low direct value for therapeutic discovery or molecular targets but may modestly inform symptomatic rehabilitation approaches and experimental designs for FOG interventions.

Useful for informing clinical care delivery and prioritizing non-pharmacological interventions but offers minimal direct mechanistic or therapeutic-discovery insights for drug development.

Relevant for safety, tolerability, and delivery-route considerations (impacting adherence and the need for alternative formulations or skin-management strategies) but offers little mechanistic insight or direct therapeutic-discovery value.

Low direct relevance to therapeutic discovery (no mechanisms or targets), but useful for improving clinical assessment, patient-reported outcomes, and trial endpoint selection for symptomatic care.

Findings can inform rehabilitation and fall-prevention strategies with clinical relevance but offer minimal actionable mechanistic insight or direct value for therapeutic drug discovery.

Direct therapeutic discovery value is low, but fostering regional collaboration could indirectly accelerate cohort building, data sharing, and trial recruitment that enable future translational PD studies.

It improves patient-reported outcome measurement and could aid clinical assessment or trial endpoint selection in Turkish-speaking populations, but provides negligible direct insight for therapeutic discovery or mechanistic targets.

Provides useful translational/clinical evidence supporting inhaled levodopa for rapid OFF-episode relief and implementation in practice, aiding symptomatic treatment decisions though it does not advance disease-modifying mechanisms.

This paper is clinically relevant and translational—summarizing evidence for a non‑pharmacologic, device‑based symptomatic therapy that can inform patient selection, safety profiles, and trial design—though it offers limited insight into disease‑modifying mechanisms.

If the JAK2-CHIP–parkinsonism link is real, it highlights a potentially actionable immune/hematopoietic mechanism (and biomarkers) that could inform repurposing of JAK-pathway interventions, but the missing abstract and likely conceptual nature limit immediate translational impact.

While not providing mechanistic or therapeutic targets, the review is moderately valuable for Parkinson's therapeutic development because validated wearable-derived digital biomarkers and AI-driven monitoring/rehabilitation can improve patient phenotyping, clinical trial endpoints, and remote…

Pending deeper interpretation.

Pending deeper interpretation.